Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP7A1 polymorphism and response to colesevelam in hypercholesterolemia
2012-001638-33Phase 3Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- May 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of colesevelam in hypercholesterolemia, sponsored by Institute for Clinical and Experimental Medicine. Primary endpoints: Response of cholesterol concentration to colesevelam by CYP7A1 polymorphism and Change in concentration of 7alpha-hydroxycholest-3-en-4-one (C4). Started May 2012; status: completed.
02
Drugs
colesevelam
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2012-001638-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001638-33.